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a b s t r a c t
PARP enzymes inﬂuence the immune system at several key points and thus modulate inﬂammatory
diseases. PARP enzymes affect immune cell maturation and differentiation and regulate the expres-
sion of inﬂammatory mediators such as cytokines, chemokines, inducible nitric oxide synthase and
adhesion molecules. Moreover, PARP enzymes are key regulators of cell death during inﬂammation-
related oxidative and nitrosative stress. Here we provide an overview of the different inﬂammatory
diseases regulated by PARP enzymes.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
1. Introduction
Poly(ADP-ribose) polymerases (PARPs) constitute a family of 17
enzymes [1] sharing a highly conserved PARP signature motif in
the catalytic domain. The prototypical PARP enzymes (PARP-1
and -2) possess a DNA binding domain enabling them to bind to
damaged DNA and thus become activated [2]. Active PARP-1 and
PARP-2 synthesize poly(ADP-ribose) polymers from NAD+ marking
proteins near the DNA damage site. Although the characterization
of the newly discovered PARP enzymes has not yet been accom-
plished, it is already apparent that PARP enzymes perform a wide
variety of tasks ranging from DNA repair, regulation of gene
expression to cell death [3].
The anti-inﬂammatory properties of PARP inhibitors have been
recognized over a decade [4] and the number of publications on
these effects is still on the rise. Our aim in the present chapter is
to provide an overview of the complex role of PARP enzymes in
inﬂammatory processes ranging from immune cell maturation to
inﬂammatory gene expression and to explain the mechanism of
protection provided by the PARP knockout phenotypes or by PARP
inhibition in inﬂammatory tissue injury.
2. Poly(ADP-ribose) polymerases in the maturation and
differentiation of immune cells
In adult mammals immune cells are formed in the bone marrow
by the division of resident stem cells. These premature immune
cells then travel to different immune organs (thymus, the Peyer’s
patches of the gastrointestinal (GI) tract, etc.) and undergo a pro-
cess called maturation in order to yield competent, functional,
non-self reactive cells that can then exit to the periphery and per-
form adequate immune functions. Although no systematic investi-
gation took place as of yet, current data suggest that different PARP
enzymes are necessary for the maturation and differentiation of
different immune cell types.
An important point during T and B cell development is the VDJ
recombination that is responsible for the generation of a wide rep-
ertoire of immunoglobulins and T cell receptors. VDJ recombina-
tion involves DNA rearrangement and thus the resolution and
rejoining of DNA strand breaks in which the elementary role of
the DNA repair machinery has been shown [5] prompting research
to assess the role of PARPs in these processes. Only minor altera-
tions have been reported in B cells of PARP-1 knockout mice. How-
ever, PARP inhibition increased the frequency of Ig class switch [6]
leading to variations in immunoglobulin class composition [7].
Moreover, the deﬁcient VDJ recombination in the T cells of SCID
(severe combined immunodeﬁciency) mice could be rescued by
knocking out PARP-1 [8] indicating the antirecombinogenic effect
of PARP-1 during T cell maturation.
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PARP-1 inﬂuences mature B cell differentiation and prolifera-
tion by binding to the Bcl6 gene in a sequence-speciﬁc manner act-
ing as a transcriptional repressor. Since Bcl6 expression is
restricted to germinal centers, where active cell division takes
place, PARP-1 binding and activation is likely to be necessary for
B cells to exit from germinal centers [9].
Both T cell function and development may be affected by PARP-
1 and -2. A recent report has described an increased number but
normal phenotype and function of Foxp3+ regulatory T cells and
consequently impaired proliferation of CD4+ T cells and suppressed
IL-2 production in PARP-1/ mice [10]. This may partly explain
suppressed inﬂammation observed in PARP-1 knockout mice in
models of T cell-mediated inﬂammatory diseases. T cell-dependent
antibody responses were also found to be impaired in PARP-1/
mice [7]. PARP-2 also affects T cell number through impairing
thymopoesis. PARP-2 was abundantly expressed in the subcapsular
zone of the thymus with decreased expression towards the center
of the thymus suggestive of its involvement in thymocyte prolifer-
ation [11]. Indeed, PARP-2 deﬁcient thymocytes die via p53-medi-
ated apoptosis that leads to decreased number of CD4+, CD8+
thymocytes in the thymus [12,13].
Impaired T cell-mediated inﬂammation can thus be attributed
to several factors, such as impaired inﬂammatory gene expression
(discussed in the next chapter) and difference in the composition
of T cell populations. Scattered data in the literature indicate that
the differentiation of other inﬂammatory cell types, such as mono-
cytes and dendritic cells may also be affected by PARP-1 [14,15].
3. Molecular events in inﬂammation regualated by poly(ADP-
ribose) polymerases
3.1. Transcription factors
PARP enzymes interact with a large number of transcription fac-
tors of which many are involved in the regulation of inﬂammatory
gene expression. The ﬁrst one identiﬁed was NFjB [16] providing
an explanation at the molecular level for the protection of PARP-1
knockout mice from endotoxin shock. Several other transcription
factors and cofactors involved in inﬂammatory regulation such as
NFAT [17,18], AP-1 [19–22], YY1 [23], sp1 [24], SIRT1 [25,26] were
also found to bemodulated by PARP-1. Recent data pointed towards
the involvement of other PARP enzymes in the transcriptional reg-
ulation of inﬂammatory processes. PARP-2 regulates the activity of
several members of the peroxisome proliferator activated receptor
family (PPARs) [27], or SIRT1 [28,29], while PARP-14 mediates
STAT6 transcription [30,31]. However, the relevance of these latter
ﬁndings in inﬂammations requires further investigation.
It is interesting to note that most transcription factors listed
above are also activated by oxidative stress, thus considered re-
dox-sensitive. It is debated whether PARP activity is necessary for
the proper activation of these transcription factors since in vitro
data suggest that DNA binding and PARP activity might be dispens-
able for NFjB activation [32]. In contrast, a large set of in vivo data
support the anti-inﬂammatory effects of PARP inhibitors. Recently
two excellent studies linked PARP1 to upstream events of NFjB
pathway by demonstrating that PARP-1 activation is necessary for
the ubiquitination and degradation of the inhibitor of NFjB kinase
(IKK) promoting NFjB activation [33,34]. The actual mode of how
PARP-1 contributes to the activation of NFjB and other transcrip-
tion factors in different models will require further investigation.
3.2. Cytokines and chemokines
Inﬂammatory cytokines such as TNFa, IL-1b, IL-6 and IL-12 are
central regulators of the inﬂammatory process orchestrated by Th1
cells. These cytokines boost the expression of other cytokines and
chemokines, adhesion molecules, matrix metalloproteinases,
inducible nitric oxide synthase (iNOS), and cyclooxygenase-2
(COX-2). PARP inhibition or the PARP-1 knockout genotype has
been shown to result in suppressed levels of the inﬂammatory
cytokines in various animal models of inﬂammation. Similarly,
many chemoattractant chemokines (e.g. IL-8, MIP-1, MIP-2, MCP-
1) were also found to be downregulated in animals lacking a func-
tional PARP-1 gene or treated with a PARP inhibitor. These changes
may represent the underlying mechanism for the inhibition of
inﬂammatory cell migration as reported in many Th1-mediated
inﬂammatory conditions.
PARPs other than PARP1 may also alter the production of che-
mokines and cytokines. Deletion of PARP-2 leads to alterations in
the transcriptome, notably in the expression of genes involved in
inﬂammatory regulation [reviewed in [35]]. Interestingly there
seems to be an overlap with the inﬂammatory genes dysregulated
upon PARP-1 ablation: e.g. Il-1b and TNFa levels were lowered
both in the absence of PARP-1 or PARP-2 [36,37]. Moreover, knock-
ing out PARP-14 enhances IL-4-induced STAT6-mediated gene
expression that impacts on immune processes notably in Th2-
mediated processes in the lungs [30,31].
3.3. Adhesion factors
Another important group of regulated proteins include different
adhesion proteins, such as cell adhesion molecules (I-CAM, V-CAM,
L-CAM) and selectins. Suppressed expression of adhesion mole-
cules on the surface of endothelial and immune cells decreases
the migration of inﬂammatory cells to the site of inﬂammation
and thus inhibits inﬂammation. In the absence, or upon inhibition
of PARP-1, the expression of these adhesion molecules is depressed
[21,38]. This effect may have a dual cause: on one hand NFjB di-
rectly regulates the expression of these genes, while on the other
hand, a secondary loop may exist, where the NFjB-regulated cyto-
kines regulate the expression of the adhesion molecules [39,40].
3.4. Inﬂammatory mediators: iNOS, COX-2 and MMPs
An important inﬂammatory gene regulated by PARP-1 is iNOS
that is responsible for NO synthesis under inﬂammatory conditions
[41,42]. NO derived from iNOS may combine with superoxide to
form peroxynitrite [43–45]. Interestingly, iNOS, under certain
pathological conditions, where iNOS substrates are limiting, may
become uncoupled and produce superoxide instead of nitrogen
monoxide [46]. This mechanism has been suggested to enhance
peroxynitrite production and tissue damage [47]. Although it is a
rather labile reactive nitrogen species, peroxynitrite can travel
through biological compartments, can diffuse through membranes
and can reach the nucleus to trigger oxidative and nitrative dam-
age to DNA, proteins and lipids [48].
As iNOS is regulated via NFjB activation, therefore PARP inhibi-
tion is capable of markedly reducing iNOS expression and nitrosa-
tive stress [21,39]. Cyclooxygenase-2 (COX-2) is also involved in
generating free radicals and has been shown to be regulated by
NFjB. In the case of COX-2, however, a more direct regulatory link
may be more important: PARP-1 has been demonstrated to bind to
the mouse COX-2 promoter region through interactions with the
inhibitory element resulting in the inhibition of COX-2 expression
[49].
Increased oxidative stress is capable of inducing redox-sensitive
enzymes, such as matrix metalloproteinases (MMPs). In addition to
proteolytic cleavage, MMPs can also be activated by free radical-in-
duced structural changes [50] and are indispensable for cellular
movements within tissues. Several studies have shown that MMP
activation during inﬂammation (e.g. MMP-9 activation in skin
inﬂammation) can be prevented by knocking out PARP-1 or by
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pharmacological PARP inhibition [21,51–54]. Moreover, tissue
inhibitors of MMPs (TIMPs) that keep MMP activity under control
are inversely regulated with MMPs [21,51,54]. It has not been
determined as of yet whether these effects are related to modula-
tion of MMP and TIMP gene expression by PARylation or PARyla-
tion controls MMP activation via regulation of cellular redox status.
From the above it is clear that PARP-1 plays a central role in
inﬂammation by inﬂuencing multiple key events such as the pro-
duction of cytokines, expression of adhesion molecules, iNOS and
COX-2 and probably MMPs and TIMPs through modulating differ-
ent transcription factors (Fig. 1.). These events form a complex sig-
naling network in which the proteins display a multilevel
interrelationship with each other. For example NFjB enhances
iNOS expression, hence oxidative stress that in turn activates both
NFjB and PARP-1/2, creating a vicious, self intensifying cycle.
Moreover, the PARP-1/2- and NFjB-dependent expression of adhe-
sion factors and MMPs contribute to inﬂammatory cell migration
and thus to oxidative stress which feeds back to both PARP-1/-2
and NFjB. This high level of complexity makes the in vivo dissec-
tion of causal relationships challenging. In the same time this cen-
tral role of PARP-1 in inﬂammatory circuitry makes these enzymes
promising targets of anti-inﬂammatory drug development.
4. Oxidative stress-induced activation of poly(ADP-ribose)
polymerases in inﬂammation
Inﬂammatory processes are associated with high level of oxida-
tive stress. The oxidants produced for example by iNOS, NADPH
oxidases, COX-2 or the mitochondrial respiratory chain cause
excessive DNA damage. Berger and colleagues [55] proposed that
severe DNA damage may lead to excessive PARP activation which
may deplete cellular NAD+ pools compromising cellular metabo-
lism. Under such conditions glycolytic ﬂux slows down [56] there-
by impairing an oxygen-insensitive metabolic pathway. Moreover,
NAD+ depletion turns on NAD+ resynthesis via nicotinamide mono-
nucleotide adenylyltransferase (NMNAT) and phosphoribosyl
pyrophosphate synthetase (PPS) at the expense of ATP. The often
marked NAD+ depletion may lead to consumption of cellular ATP
[3,55]. Under low ATP, low NAD+ conditions, mitochondrial F1/F0
ATPase turns to function as ATPase rather than ATP synthase [57]
further deteriorating energy depletion. Compromised cellular
energetics may contribute to the pathological sequalae of excessive
poly(ADP-ribosyl)ation in inﬂammations.
In severe oxidative stress, cellular energy status also affects cell
death pathways. Failure of DNA repair initiates apoptotic cell
death. Since apoptosis also relies on ATP, cleavage of PARP-1 and
-2 by caspase-3 and -7 may be viewed as a preventive measure
aiming at the conservation of cellular ATP [58,59]. During apopto-
sis cellular content is crosslinked and cells disintegrate into mem-
brane-coated vesicles marked with the ‘‘eat-me’’ signal
phosphatidyl-serine for phagocytosis. These vesicles are then
cleared by inﬁltrating macrophages and resident, neighboring cells,
therefore no leakage of cellular content occurs under apoptosis.
If the apoptotic process cannot be executed (e.g. due to lack of
sufﬁcient amount of ATP or inhibition of caspases), then cells may
die by necrosis. Necrosis is characterized by the lack of themorpho-
logical and biochemical hallmarks of apoptosis. Most notably, plas-
ma membrane integrity is compromised early during necrosis and
cellular content may leak into the environment. Such leakage may
cause secondary tissue injury by causing further inﬂammation. Ini-
tially necrosis was thought to be an uncontrolled form of cell death.
However, recently programmed features and necrotic signaling
molecules (RIP kinases, non-caspase proteases, cyclophylline D)
have been identiﬁed in necrosis indicating that necrosis is not nec-
essarily beyond regulatory control [60]. Overactivation of PARP-1
has been increasingly recognized as a mediator of necrosis that is
highly amenable to pharmacological intervention. In severe oxida-
tive stress for example PARP-1-mediated necrosis serves as a
Fig. 1. PARP as a central regulator of inﬂammatory pathways. DNA damage triggers the activation of PARP-1 and -2. PARP activation has proinﬂammatory properties through
lowering the number of inhibitory T cells, enhancing antigen presentation by dendritic cells. Moreover, oxidative stress stimulates redox-sensitive transcription factors that
are co-activated by PARP-1. These transcription factors regulate the expression of chemokines, adhesion molecules, iNOS, MMP and COX-2. These effects lead to inﬂammatory
cell homing, tissue invasion and activation which in turn further enhances inﬂammation-related oxidative stress and a vicious, self-intensifying cycle of inﬂammation.
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backup mechanism eliminating severely injured cells even when
the apoptoticmachinery is incapacitated. In fact PARP activation ac-
tively switches the default apoptotic cell death towards necrosis.
When PARP activity is inhibited or parp-1 gene is knocked out,
necrosis can be reverted to apoptosis [3,61–63].
5. Inﬂammatory diseases mediated by poly(adp-ribose)
polymerases
Previously we reviewed the molecular determinants for the
proinﬂammatory role of PARylation. These mechanisms have been
validated in a vast array of inﬂammatory conditions identifying a
large number of diseases where PARP inhibition may provide ther-
apeutical beneﬁts (detailed in Table 1.). It is important to note that
almost all organs display inﬂammatory conditions that can be
attenuated by PARP inhibition indicating that PARP affects central
events in inﬂammatory signaling. The diseases listed in Table 1 are
quite diverse in terms of etiology, pathomechanism (infectious,
autoimmune, allergic, irritation-induced, etc.) being organ-re-
stricted versus generalized inﬂammations. Most of the conditions
listed are mediated by IL-2- and IFNc-producing Th1 cells. Others
such as asthma are typical Th2-mediated conditions dominated
by the production of Th2 cytokines such as IL-4, -5 and -14. Recent
reinterpretation of Th1/Th2 dichotomy as triggered by the identiﬁ-
cation of the novel Th17 cell type shed light on the complexity of
immunoregulation in inﬂammatory diseases such as collagen-in-
duced arthritis (CIA) and experimental allergic encephalomyelitis
(EAE), animal models of the human diseases rheumatoid arthritis
and multiple sclerosis, respectively. These latter two models are
now considered as Th17 rather than Th1-mediated conditions.
(The new Th17 cell type is characterized by the production of
IL17 and 23.)
Since PARP-1 regulates such central events of inﬂammatory sig-
naling as the activation of NFjB and AP-1 transcription factors,
therefore it is not surprising that PARP inhibition has beneﬁcial ef-
fects in a wide spectrum of inﬂammatory conditions. Nonetheless,
the mechanism of the beneﬁcial effects of PARP inhibition may dif-
fer between Th1 and Th2-mediated conditions. Whereas the NFjB
co-activator function of PARP-1 has been made responsible for the
effects of PARP inhibitors in Th1 diseases (and this may also con-
tribute to the pathology of Th2-mediated conditions), recently a
novel mechanism has been described for asthma, a prototypical
Th2-mediated disease. Datta et al. [64] have demonstrated in a
murine model of asthma that inhibition of eosinophil migration
in PARP-1/ mice is controlled at a step downstream of IL-4 and
upstream of IL-5. PARP-1 was found to stabilize STAT-6 protein
(without affecting mRNA) in an allergen-stimulation dependent
manner. STAT-6, a central regulator of IL-5 expression undergoes
degradation in the absence of functional PARP-1. This example ni-
cely illustrates that the role played by PARPs in inﬂammation is
complex and may differ in various forms of inﬂammation.
An inﬂammatory component has recently been identiﬁed as an
important pathogenetic factor in the development of several
chronic diseases of the cardiovascular system such as atherosclero-
sis, chronic heart failure and cardiovascular aging [65]. Both PARP
inhibition and knockout of PARP-1 have been shown to have ben-
eﬁcial effects in murine models of these conditions [66–70].
Although the molecular mechanisms underlying these positive ef-
fects are not well understood, it is plausible to hypothesize that the
anti-inﬂammatory effects of PARP inhibition may contribute to im-
proved clinical parameters observed in these models. PARP activa-
tion is associated with numerous human inﬂammatory diseases
such as allograft rejection, various forms of shock, arthritis, colitis,
diabetic complications, transplant rejection, COPD [3,71,72] open-
ing the door for the possible clinical use of PARP inhibitors in these
diseases. Several clinical trials have been conducted with PARP
inhibitors demonstrating their good tolerability [73,74] and their
potential as anti-cancer agents [75]. Moreover, in the study
Table 1
Inﬂammatory diseases mediated by poly(ADP-ribosyl)ation. PARPi – PARP inhibition, KO – knockout, all other abbreviations in text.
Organ Disease Protection provided by Ref.
Multiorgan diseases Sepsis PARPi [82]
Endotoxic shock PARP-1 K.O., PARPi [16,83]
Heamorrhagic shock PARP-1 K.O. [84]
Central nervous system Allergic encephalomyelitis PARPi [85]
Meningitis-related central nervous system complications PARP-1 K.O., PARPi [86]
Myelitis PARPi [87]
Astrocyte activation PARP-1 KO
PARP-2 KO
PARP-3 KO
[36]
Joints Arthritis [88]
Temporomandibular joint disorder PARPi [89]
Bones Cherubism Tankyrase activation [79]
GI tract Colitis PARP-1 and -2 K.O. [37,38]
Pancreatitis PARP-1 K.O. (PARP-2 has no effect), PARPi [90]
Peritonitis PARP-1 K.O. [91]
Respiratory system Asthma PARPi [64,92–94]
PARP-14 activation [31]
COPD – [95]
Pleuritis PARPi [96]
ARDS PARP-1 K.O., PARPi [97]
Ventilation-induced inﬂammation PARPi [98]
Rejection of tracheal allografts PARPi [99]
Skin Contact hypersensitivity PARP-1 K.O., PARPi [21,51,100]
Irritative dermatitis PARP-1 K.O., PARPi [21,51]
Sunburn-related dermal inﬂammation PARPi [101]
Eye Uveitis PARPi [102]
Ear Cochlear lateral wall damage PARP-1 K.O. [103]
Skeletal muscle Movement-induced damage associated inﬂammation [104]
Kidneys Renal hypertrophy PARPi [105]
Cisplatin-induced kidney inﬂammation PARPi, PARP-1 K.O. [106]
Diabetic nephropathy PARPi [107,108]
Cardiovascular system Atherosclerosis PARPi [54,109–111]
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utilizing the PARP inhibitor INO1001, Morrow and colleagues have
shown that administration of INO1001 resulted in a tendency to
reduce IL-6 and CRP levels pointing towards suppressed inﬂamma-
tion [73].
In addition to the beneﬁcial effects of PARP inhibitors and pro-
tection provided by knockout phenotypes, the role of PARPs in
inﬂammation is also indicated by association of certain PARP-1
promoter haplotypes and SNPs with diseases. Such associations
have been reported for systemic lupus erythematosus [76], auto-
immune nephritis [76] or rheumathois arthritis [77] further sup-
porting a possible link between PARP-1 and autoimmune
inﬂammation.
6. Conclusion
As detailed above, PARP activation is a key event in the propa-
gation of inﬂammation and PARP inhibition suppresses inﬂamma-
tion at multiple molecular events (for overview, see Fig. 1). Key
components of the anti-inﬂammatory effects of PARP inhibition
are the following: (1) Members of the PARP family may be neces-
sary for the maturation and differentiation of cells of the immune
system with PARP-1 and -2 playing a role in the regulation of T cell
function. (2) PARPs are integral and central players of the self
intensifying circle of inﬂammation by regulating the expression
of inﬂammatory mediators such as cytokines, chemokines, adhe-
sion molecules, iNOS and COX-2. A key molecular event in this reg-
ulation is the interaction of PARP-1 with transcription factors such
as NFjB and AP-1. (3) Free radicals may cause DNA damage and
activate PARP-1 and -2. In case of severe DNA damage, PARP over-
activation may cause cell dysfunction and cell death which may
contribute to inﬂammation accompanying severe conditions such
as shock and ischemia–reperfusion injuries.
Several open questions concerning PARP-related inﬂammatory
diseases remain to be resolved. These include but are not limited
to the mechanism of gender bias described in the role of PARP in
inﬂammations [78]. Furthermore, it will be important to determine
the involvement of further members of the PARP family in the reg-
ulation of inﬂammatory processes. Some of them have already been
shown to associate with inﬂammatory pathologies: such as PARP-2
(reviewed in [35]), PARP-3 [36], tankyrases [79], or PARP-14 [30,31].
Moreover, poly(ADP-ribose) glycohydrolase has been implicated in
the regulation of immune functions [80,81] underlining the central
role of poly(ADP-ribosyl)ation in inﬂammation. A key question is
whether the powerful anti-inﬂammatory effects of PARP inhibitors
as observed in animal models can be translated to human diseases
and to determine the risk beneﬁt ratio of acute and chronic
administration of PARP inhibitors in non-cancer patients.
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